Drugmaker Indivior profit slumps on higher legal, promotion costs
Share:
(Reuters) - Indivior reported a steep fall in quarterly profit on Thursday, as the British drugmaker spent heavily on promoting its latest opioid addiction treatment and incurred higher costs related a U.S. investigation into its best-selling drug.The company, spun-off from Reckitt Benckiser in 2014, faces a $3 billion(2.46 billion pounds) fine under criminal charges pressed by the United States for illegally marketing Suboxone, Indivior's best-selling opioid addiction treatment. Indivior,..